The Obesity Pricing Paradigm Gets Even More Complex With Novo’s $199 Wegovy Offer
Shares:
This has not been a great week for explanatory takes on the Inflation Reduction Act “negotiation” process. I did some whining yesterday about Reuters’ micron-deep assessment of the situation, and
If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
The United States does not have a government-sanctioned group that makes determination of the value of a given drug (and it still won’t, even after the Inflation Reduction Act is